AI Engines For more Details: Perplexity Kagi Labs You
Asthma: Pranlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children. By blocking leukotriene receptors, pranlukast helps to reduce airway inflammation, bronchoconstriction, and mucus production, thereby improving breathing and reducing the frequency and severity of asthma symptoms such as coughing, wheezing, chest tightness, and shortness of breath.
Allergic Rhinitis: Pranlukast is also used for the treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis. By inhibiting the effects of leukotrienes, pranlukast helps to alleviate symptoms such as nasal congestion, sneezing, runny or itchy nose, and nasal itching, associated with allergic reactions to environmental allergens such as pollen, dust mites, and pet dander.
Exercise-Induced Bronchoconstriction (EIB): Pranlukast may be used to prevent exercise-induced bronchoconstriction, a condition characterized by the narrowing of the airways following physical exertion. By blocking leukotriene receptors, pranlukast helps to prevent the bronchoconstriction and inflammation triggered by exercise, allowing individuals with asthma or exercise-induced bronchoconstriction to engage in physical activities more comfortably.
Chronic Obstructive Pulmonary Disease (COPD): While not typically a first-line treatment, pranlukast may be used as an adjunctive therapy in the management of chronic obstructive pulmonary disease (COPD), particularly in patients with features of asthma-COPD overlap syndrome (ACOS). By reducing airway inflammation and bronchoconstriction, pranlukast may help improve symptoms and lung function in some individuals with COPD.
Prevention of Respiratory Symptoms: Pranlukast may be prescribed to prevent respiratory symptoms triggered by exposure to allergens or other environmental factors known to induce asthma exacerbations or allergic reactions. By blocking leukotriene receptors, pranlukast helps to mitigate the inflammatory response in the airways, reducing the likelihood of symptom flare-ups.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2.2 | 0.4 | 4.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
| Allergies | 1.4 | 1.9 | -0.36 |
| Allergy to milk products | 0.9 | 0.1 | 8 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 2 | 4.4 | -1.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.6 | 0 |
| Ankylosing spondylitis | 2.1 | 1.2 | 0.75 |
| Anorexia Nervosa | 2 | -2 | |
| Antiphospholipid syndrome (APS) | 1.8 | 1.8 | |
| Asthma | 0.8 | -0.8 | |
| Atherosclerosis | 0.8 | 1.7 | -1.13 |
| Atrial fibrillation | 2.6 | 1.3 | 1 |
| Autism | 5.7 | 4.8 | 0.19 |
| Barrett esophagus cancer | 0.6 | 0.4 | 0.5 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 0.8 | 1.7 | -1.13 |
| Brain Trauma | 0.8 | -0.8 | |
| Cancer (General) | 0.1 | 0.1 | |
| Carcinoma | 1.6 | 1.2 | 0.33 |
| Celiac Disease | 1.5 | 1.5 | 0 |
| Cerebral Palsy | 0.7 | 1.6 | -1.29 |
| Chronic Fatigue Syndrome | 3.8 | 4.2 | -0.11 |
| Chronic Kidney Disease | 1.3 | 1.8 | -0.38 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 0.9 | 1 |
| Chronic Urticaria (Hives) | 0.9 | 0.9 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 1.7 | -1.83 |
| Colorectal Cancer | 3.2 | 0.4 | 7 |
| Constipation | 0.6 | 0.8 | -0.33 |
| Coronary artery disease | 1.1 | 1 | 0.1 |
| COVID-19 | 3.7 | 9.2 | -1.49 |
| Crohn's Disease | 3.6 | 3.2 | 0.13 |
| cystic fibrosis | 0.2 | 0.8 | -3 |
| deep vein thrombosis | 0.2 | 1.4 | -6 |
| Depression | 1.9 | 4.9 | -1.58 |
| Dermatomyositis | 0.4 | 0.4 | |
| Eczema | 0.6 | 1.1 | -0.83 |
| Endometriosis | 1.5 | 1 | 0.5 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.3 | 0.6 | 1.17 |
| Fibromyalgia | 0.8 | 2 | -1.5 |
| Functional constipation / chronic idiopathic constipation | 2.6 | 2.9 | -0.12 |
| gallstone disease (gsd) | 1.2 | 0.8 | 0.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 1 | -0.11 |
| Generalized anxiety disorder | 0.9 | 0.7 | 0.29 |
| Glioblastoma | 0.4 | -0.4 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.3 | 0.8 | -1.67 |
| Halitosis | 0.9 | 0.4 | 1.25 |
| Hashimoto's thyroiditis | 1.9 | 0.3 | 5.33 |
| Hidradenitis Suppurativa | 0.7 | 0.3 | 1.33 |
| High Histamine/low DAO | 0.6 | 0.5 | 0.2 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.1 | 0.6 | -5 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.2 | 2.3 | -0.92 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 1.8 | -1.8 | |
| Inflammatory Bowel Disease | 1.8 | 6.2 | -2.44 |
| Insomnia | 1 | 0.8 | 0.25 |
| Intelligence | 0.4 | 0.9 | -1.25 |
| Intracranial aneurysms | 1.1 | 1.1 | |
| Irritable Bowel Syndrome | 2.1 | 1.8 | 0.17 |
| Liver Cirrhosis | 3.2 | 2.4 | 0.33 |
| Long COVID | 3.8 | 4.7 | -0.24 |
| Low bone mineral density | 0.9 | -0.9 | |
| Lung Cancer | 0.1 | 0.8 | -7 |
| Mast Cell Issues / mastitis | 0.4 | 0.9 | -1.25 |
| ME/CFS with IBS | 0.4 | 1.7 | -3.25 |
| ME/CFS without IBS | 0.5 | 0.3 | 0.67 |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 3.1 | 3 | 0.03 |
| Mood Disorders | 3.5 | 4.9 | -0.4 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.3 | 4 |
| Multiple Sclerosis | 2.2 | 3.4 | -0.55 |
| Multiple system atrophy (MSA) | 0.8 | -0.8 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.7 | 0.1 | 6 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 3.1 | -0.82 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.6 | 2.6 | 0.38 |
| obsessive-compulsive disorder | 4.1 | 3.4 | 0.21 |
| Osteoarthritis | 0.9 | 0.5 | 0.8 |
| Osteoporosis | 1.2 | 0.6 | 1 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 2.6 | 5.5 | -1.12 |
| Polycystic ovary syndrome | 1.4 | 1.6 | -0.14 |
| Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| Psoriasis | 1.6 | 2.1 | -0.31 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 1.9 | 1.16 |
| Rosacea | 1.3 | 0.5 | 1.6 |
| Schizophrenia | 2 | 1.7 | 0.18 |
| scoliosis | 0.4 | 0.5 | -0.25 |
| Sjögren syndrome | 2.8 | 1 | 1.8 |
| Sleep Apnea | 1.5 | 1.5 | 0 |
| Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.2 | 1.2 | 0 |
| Systemic Lupus Erythematosus | 2.3 | 1.4 | 0.64 |
| Tic Disorder | 0.9 | 0.9 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 2.6 | 1.2 | 1.17 |
| Type 2 Diabetes | 3.4 | 3.4 | 0 |
| Ulcerative colitis | 1.1 | 2.9 | -1.64 |
| Unhealthy Ageing | 4.2 | 1.9 | 1.21 |
| Vitiligo | 0.9 | 0.8 | 0.13 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]
